This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other persistent delusional disorders기타 지속성 망상장애 (기타지속성망상증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F22.8 (Other persistent delusional disorders) | Special Copayment Reduction: V161 (severe intractable disease, 5 years)
B. SynonymsDelusional dysmorphophobia, involutional paranoid state, litigious paranoia
C. Adult onsetPossible first manifestation in adulthood: very high — the delusional type of body dysmorphic disorder commonly begins in late adolescence to early adulthood, and litigious paranoia typically begins after middle adulthood.
1. HistoryF22.8 was newly established in ICD-10 to encompass persistent delusional states not belonging to F22.0; includes the delusional type of body dysmorphic disorder, litigious paranoia, etc.
2. CausesCombined action of serotonin-dopamine dual abnormality (BDD delusional type), cognitive bias (appearance-related distorted perception), perfectionism and impaired self-esteem, and sociocultural appearance pressure.
3. GeneticsHeritability in body dysmorphic disorder twin studies about 44-65%; shared genetic factors with obsessive-compulsive disorder and social anxiety disorder; association studies of SLC1A1 and SERT polymorphisms reported.
4. General epidemiologyGeneral population prevalence of body dysmorphic disorder about 1.7-2.4%; the delusional type accounts for about 25-40% of all BDD; exact prevalence of litigious paranoia unknown; median age of onset about 16-17 years (BDD delusional type).
5. PathophysiologyOrbitofrontal cortex-striatal circuit abnormality (BDD), detail-focused processing bias in the visual cortex, serotonin 5-HT1A and 2A receptor abnormalities, and dopamine hypersensitivity contribute to the formation of delusional beliefs.
6. SymptomsDelusional conviction about an appearance defect (BDD delusional type), persistent litigation behavior over violation of legal rights (litigious paranoia), involutional paranoid state (arising after loss of occupation or status).
7. SignsMirror checking, comparing, and avoidance behaviors (BDD), repeated requests for surgery or cosmetic procedures, preparation of voluminous documents and repeated complaints related to litigation, affect generally preserved.
8. ScreeningBDD-YBOCS (Yale-Brown Obsessive Compulsive Scale modified for body dysmorphic disorder), BDD Questionnaire (BDDQ), screening interviews for patients attending dermatology and plastic surgery; no standard screening tool for litigious paranoia.
9. DiagnosisICD-10 F22.8: persistent delusion not meeting F22.0 criteria; complete absence of insight in the BDD delusional type; differentiation from obsessive-compulsive disorder, social anxiety, and dysmorphophobia (nondelusional) is essential.
10. TreatmentHigh-dose SSRI (fluoxetine, escitalopram) + antipsychotic (BDD delusional type); cognitive behavioral therapy (exposure and response prevention); litigious paranoia: antipsychotic + supportive treatment.
11. PrognosisThe BDD delusional type may respond partially to SSRIs; litigious paranoia commonly has a chronic course; suicide risk (20-30% of BDD patients have attempted suicide) is clinically important.
12. PreventionMedia literacy education (easing sociocultural appearance pressure), adolescent mental health screening, strengthened mental health assessment before cosmetic surgery or dermatology referral, early cognitive behavioral therapy intervention.
13. ReferencesPhillips KA. Body Dysmorphic Disorder: Advances in Research and Clinical Practice. Oxford University Press. 2017 … and 9 other papers

1. History

Other persistent delusional disorders (F22.8) is a classification code established in ICD-10 to encompass various clinical states that do not fully meet the diagnostic criteria for F22.0 (delusional disorder) but have persistent, non-bizarre delusions at their core. The clinically most important states in this category are the delusional type of body dysmorphic disorder (BDD) and litigious paranoia.

The history of body dysmorphic disorder begins in 1891, when the Italian psychiatrist Enrico Morselli first proposed the term "dysmorphophobia." Morselli described the clinical picture of patients whose social functioning was markedly impaired by persistent, intense preoccupation with their appearance, and named it with the concept of a phobia of appearance defects. Kraepelin subsequently classified it as a condition with obsessional features, and Freud described this phenomenon as a form of neurosis.

In modern diagnostic systems, BDD was first included in DSM-III in 1980 as one of the Atypical Somatoform Disorders, and in DSM-III-R in 1987 it was named Body Dysmorphic Disorder and included in the somatoform disorders group. In DSM-5 (2013), BDD was moved to the Obsessive-Compulsive and Related Disorders group, and an insight spectrum was specified, with the type with absent insight/delusional beliefs specifically described. This type corresponds to "delusional dysmorphophobia" of ICD-10 F22.8.

Litigious paranoia (querulous paranoia) originated in 19th-century German psychiatry from the description of patients who incessantly file legal complaints and lawsuits under an obsessive belief that their legal rights have been unjustly violated. They continually go to courts, government offices, and the media to correct the original harm, and show a pattern of appealing to higher authorities without being satisfied even by partial victories. This condition was included in ICD-10 as "litigious paranoia" under F22.8. Involutional paranoid state describes a state in which paranoid beliefs arise in middle or old age after experiencing loss of occupational status, social role, or physical health.


2. Causes

The various states included in other persistent delusional disorders (F22.8) each have somewhat different causal models, but in common the combined action of neurobiological vulnerability, cognitive bias, and sociocultural factors is emphasized.

Causes of the delusional type of body dysmorphic disorder: Serotonergic neurotransmission abnormality is the core neurobiological factor of BDD, which is also supported by the treatment response to SSRIs. It is proposed that abnormality of the serotonin-2A (5-HT2A) receptor affects the inhibitory regulatory function of the orbitofrontal cortex (OFC), causing rumination and obsessive preoccupation. Dopamine hypersensitivity can assign excessive salience to appearance-related stimuli and strengthen delusion-level conviction. Increased detail-focused processing in the visual cortex, with a tendency to overinterpret normal appearance variations as defects, has been observed in functional imaging studies.

Cognitive bias: Selective attention to appearance and biased interpretation are prominent in the BDD delusional type. Self-referential interpretation that others' gaze is focused on one's physical defects, cognitive distortion that catastrophically evaluates appearance changes, and a vicious cycle mechanism in which compulsive checking in the mirror rather strengthens anxiety contribute to maintaining the delusion. At the cognitive level, perfectionism and low self-esteem increase vulnerability to BDD onset.

Sociocultural factors: Excessive social emphasis on appearance and body, the media's presentation of unrealistic appearance standards, and experiences of appearance comparison within peer groups promote the onset of the BDD delusional type in vulnerable individuals. Experiences of appearance-related teasing or abuse in childhood are reported to markedly increase the risk of BDD onset.

Causes of litigious paranoia: A process in which paranoid interpretation is strengthened starting from an experience of actual or perceived unfair treatment is proposed as the mechanism of onset. Damaged self-esteem, a sense of loss of control, and hypersensitivity to injustice are psychological vulnerability factors for litigious paranoia. A rigid cognitive style, high moral standards, and a hostile attribution bias toward others' behavior are contributing factors.


3. Genetics

The genetics of other persistent delusional disorders can be informed mainly by research on body dysmorphic disorder (BDD), and systematic genetic studies of litigious paranoia or involutional paranoid state are very limited.

Heritability of body dysmorphic disorder: Twin studies estimate the heritability of BDD at about 44-65%, a level similar to that of obsessive-compulsive disorder (40-65%). In family studies, the risk of not only BDD itself but also obsessive-compulsive disorder, social anxiety disorder, and major depressive disorder is increased in first-degree relatives of BDD patients. This suggests that BDD shares part of its genetic basis with the obsessive-compulsive spectrum disorders.

Candidate genes: There are study results indicating that specific polymorphisms of the serotonin transporter gene (SLC6A4; 5-HTTLPR) are associated with the risk of BDD and obsessive-compulsive disorder. The glutamate transporter gene (SLC1A1) is associated with obsessive-compulsive spectrum disorders and is being studied as a candidate gene in BDD as well. There are also reports that variants of the dopamine receptor gene (DRD4) are related to obsessive-compulsive spectrum disorders. However, the replication level of these candidate gene studies is still low.

Current status of GWAS: Large-scale genome-wide association studies (GWAS) of BDD have not yet been conducted. It has been proposed that obsessive-compulsive disorder GWAS results (PTPRD, DLGAP1, etc.) may also be relevant to BDD, but direct verification is lacking. Larger BDD-specific GWAS are needed in the future to understand the genetic architecture.

Clinical significance: Because the risk of BDD is higher in individuals with a family history of obsessive-compulsive disorder, early BDD evaluation is recommended when family members of OCD patients show excessive appearance-related preoccupation. The delusional type of BDD (F22.8) may lie on a genetic continuum with the non-delusional type (F42, the BDD subtype of obsessive-compulsive disorder), but there is not yet research that clearly distinguishes the genetic differences between the two types.


4. General epidemiology

Systematic epidemiological data on the overall prevalence of other persistent delusional disorders (F22.8) are limited, and data on the delusional type of body dysmorphic disorder, which is mainly included in this category, are referenced.

Epidemiology of body dysmorphic disorder (BDD): The lifetime prevalence of BDD in the general population is estimated at about 1.7-2.4%. It occurs at all ages including adolescence, with a mean age of onset of about 16-17 years, relatively early. The average time from symptom onset to diagnosis is often 10-15 years, so diagnostic delay is a serious problem. Among these, the delusional type (the type with completely absent insight) is reported to account for about 25-40% of all BDD. The male-to-female ratio of BDD is about 1:1, but men have more genital-related complaints and women more skin- and hair-related complaints.

Prevalence of BDD in special clinical groups: A BDD prevalence of about 5-15% in plastic surgery and dermatology patients, about 4-8% in orthodontic patients, and about 9-26% in patients of hair-loss clinics is reported. This suggests the risk that meaningless cosmetic procedures are repeated without diagnosis, and supports the need for screening assessment in these specialties. A BDD prevalence of about 7-13% is reported in psychiatric inpatients.

Epidemiology of litigious paranoia: Epidemiological data on the exact prevalence of litigious paranoia (querulous paranoia) are lacking. There are clinical reports that this condition is found not infrequently in analyses of cases referred for court-related mental health evaluation, but systematic epidemiological studies are very limited. Onset is more often after middle adulthood (40s-60s) and tends to be slightly more common in men.

Situation in Korea: Domestic BDD epidemiological data are scarcer than in the West, but considering the characteristics of Korean society, which has strong sociocultural pressure on appearance, the prevalence is presumed not to be low. It should be noted that in Korea, with its high rate of cosmetic surgery, repeated requests for cosmetic surgery and dissatisfaction with the results can be a clinical indicator of the BDD delusional type.


5. Pathophysiology

The pathophysiology of other persistent delusional disorders differs somewhat depending on the included conditions, and the most neurobiological research has concentrated on the BDD delusional type.

Neurobiology of the delusional type of body dysmorphic disorder: Hyperactivity of the orbitofrontal cortex (OFC)-striatal circuit is proposed as the core neural mechanism of obsessive rumination and preoccupation behaviors (mirror checking, comparing, avoidance). The OFC is involved in salience assessment and impulse control, and hyperactivity of this circuit leads to excessive salience assigned to appearance-related stimuli and induction of compulsive preoccupation behaviors. In fMRI studies, an abnormal activation pattern of the fronto-striatal circuit and amygdala hyperactivation were observed when BDD patients looked at their own faces.

Visual processing bias: There is neuroimaging and neuropsychological evidence that in BDD patients the visual cortex excessively activates detailed, analytic processing while holistic, Gestalt processing is reduced. Because of this bias, minor appearance changes or features that ordinary people would not notice are experienced as prominent defects. A detail-biased processing pattern of BDD patients was confirmed in a composite face recognition task.

Emotion regulation abnormality: Amygdala hyperactivity and reduced emotion-regulating function of the prefrontal cortex cause excessive emotional reactions to negative appearance-related stimuli. Negative automatic thoughts about appearance, shame, and disgust form a vicious cycle that reinforces avoidance behavior and compulsive checking. This emotion regulation abnormality contributes to sustaining delusion-level conviction.

Pathophysiology of litigious paranoia: The core is a process in which a grievance that started from an actual experience of unfairness becomes paranoid through cognitive restructuring. The jumping-to-conclusions bias and confirmation bias strengthen preoccupation with the unfairness, and the process of interpreting every new event to fit the existing narrative of victimization maintains the litigation behavior. In terms of brain structure, mechanisms similar to those of delusional disorder (F22.0) are presumed to be involved, but specialized research is lacking.


6. Symptoms

The symptoms of other persistent delusional disorders (F22.8) vary by the included subtype, and while they share the common characteristic of persistent delusions, their content and pattern are distinct.

Delusional dysmorphophobia (Delusional BDD): The belief of having a defect in one's appearance appears as delusion-level conviction. Even though the defect is actually very slight or not observed at all by others, the patient is convinced that it is ugly and deformed. There is specific delusional content of a serious defect in one's nose, skin, hair, body shape, or facial features, and with insight completely absent, the belief does not change even when others try to persuade or refute it with photographs and the like. Accordingly, behaviors appear such as spending hours in front of a mirror (checking), conversely avoiding mirrors completely, comparison with others, avoidance of being photographed, and refusal to go out. The patient repeatedly requests cosmetic surgery or skin procedures, is not satisfied with the results, and repeats a pattern of blaming the treating physician or seeking another doctor. The risk of suicidal ideation and attempts is higher than in ordinary BDD.

Litigious paranoia (Querulous paranoia): Under a strong belief of having been treated unfairly at work, in legal transactions, in neighbor relationships, and so on, the patient incessantly files complaints and lawsuits with courts, administrative agencies, and the media to correct this unfairness. A characteristic feature is not being satisfied even when partial victory or partial resolution is achieved, and demanding greater compensation or intervention by a higher authority. An expanded interpretation may appear that lawyers, judicial bodies, and the persons involved are also party to the conspiracy. All the energy of daily life is concentrated on the legal struggle, and occupational and family relationships are seriously damaged.

Involutional paranoid state: A state in which paranoid beliefs emerge after experiences of loss such as loss of job, retirement, decline in physical ability, or bereavement. Beliefs that others despise or take advantage of the patient and the idea that those around the patient gossip about him or her appear, and it often arises against a background of depressed mood.


7. Signs

The clinical signs of other persistent delusional disorders (F22.8) are differentiated by the included subtype, and characteristic findings are observed in psychiatric interview and physical observation.

Signs of the BDD delusional type: Repeated mention of and excessively detailed description of appearance-related body parts during the interview are characteristic. Behavior to cover or conceal appearance-related parts (heavy makeup, hats, excessive clothing) is observed. Traces of self-treatment of the skin surface (excessive skin care, skin damage from self-injury, marks from tools such as tweezers and cotton swabs) may be found on physical examination. Affect expresses marked anxiety, shame, and disgust on the theme of appearance, and generally appropriate affect is maintained in areas other than this theme. A visual detail-processing bias may be observed on neuropsychological testing.

Signs of litigious paranoia: The patient often brings voluminous documents (complaint documents, court documents, diaries, etc.) to the interview and describes the story of the unfairness in great detail and systematically. A logical and persuasive style of narration (so-called "systematized delusion") is characteristic, and to an outside observer the patient's claims may at first sound valid. Anger and resentment are prominent in affect, and strong hostility toward the persons involved may be expressed. Overall cognitive function is preserved.

Functional assessment: In patients with the BDD delusional type, academic, occupational, and social relationship functioning is commonly seriously impaired. Morning preparation time may amount to several hours, or the patient may have given up going out altogether. In patients with litigious paranoia, occupational functioning is seriously impaired by the time invested in litigation, and relationships with family also deteriorate.


8. Screening

Screening for other persistent delusional disorders (F22.8) has developed mainly around the BDD delusional type, and screening in cosmetic-related specialties such as dermatology, plastic surgery, and orthodontics is especially important.

BDD screening tools: The BDD-Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS) is the standard clinical scale for assessing the severity of BDD symptoms. The Body Dysmorphic Disorder Questionnaire (BDDQ) is a simple 4-item self-report screening tool used to screen dermatology and plastic surgery patients. The sensitivity and specificity of the BDDQ are relatively high, making it useful in clinical settings. The Coles Questions are also used as an auxiliary clinical interview tool to identify BDD-specific symptoms (mirror checking, comparison behavior).

Insight assessment: Insight assessment to distinguish the delusional type (F22.8) from the non-delusional type (obsessive-compulsive disorder subtype) of BDD is important. The insight subscale of the BDD-YBOCS and the PANSS insight item are used. The most important is a clinical interview that directly asks the patient about the possibility that the appearance belief is mistaken and checks the response. Distinguish whether insight is completely absent (delusional level) or partially present, and reflect this in the treatment plan.

Screening in plastic surgery and dermatology practice: The possibility of BDD is evaluated in patients who repeatedly request cosmetic surgery or skin procedures, repeatedly express dissatisfaction with procedure results, or excessively emphasize a very minor appearance problem. Establishing a system for psychiatric consultation before surgery contributes to both patient safety and protection of medical staff.


9. Diagnosis

The diagnosis of other persistent delusional disorders (F22.8) encompasses persistent delusional states in the ICD-10 F22 category that do not meet F22.0, and specific diagnostic criteria are applied according to each subtype.

ICD-10 F22.8 diagnostic criteria: Applies when there is a persistent delusion lasting 3 months or more but the typical criteria of F22.0 (delusional disorder) are not fully met, or the delusional content is diverse and cannot be classified as a single diagnostic type. Organic causes (brain lesion, drugs, medical illness) must be excluded. The criteria for schizophrenia, schizoaffective disorder, or psychosis with mood disorder must not be met.

Diagnosis of the BDD delusional type: Diagnosed by meeting the DSM-5 BDD diagnostic criteria + completely absent insight (absent insight/delusional beliefs specifier). There must be delusion-level conviction about an appearance defect that is not observed by others or is very slight, causing clinically significant distress or functional impairment. It must not be better explained by an eating disorder (preoccupation with weight and body shape) or obsessive-compulsive disorder (content other than BDD).

Differential diagnosis: The main differential diagnoses are obsessive-compulsive disorder (BDD subtype, with insight—even if partial), social anxiety disorder (appearance-related anxiety but not delusion-level), somatoform disorder/hypochondriasis (fear of physical disease predominates), eating disorder (distortion of body shape but centered on weight and diet), conversion disorder, delusional parasitosis (differentiation from actual dermatological disease), and psychotic mood disorder. Litigious paranoia is differentiated from paranoid personality disorder (does not reach delusion level), delusional disorder of the persecutory type (other delusional content than legal), psychosis with mood disorder, and cognitive decline.

Diagnostic ancillary tests: Brain MRI (to exclude organic causes), blood tests (thyroid function, autoimmune, syphilis, etc.), dermatology and plastic surgery consultation (objective assessment of the appearance defect in the BDD delusional type), and neuropsychological testing (visuospatial processing assessment, executive function assessment) are used to aid diagnosis.


10. Treatment

Treatment of other persistent delusional disorders (F22.8) differs by subtype, and the evidence for treatment of the BDD delusional type is the best established.

BDD delusional type — SSRI: Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line drug treatment across all BDD, including the delusional type. High doses are often needed (fluoxetine 60-80 mg/day, escitalopram 20-40 mg/day, fluvoxamine 250-300 mg/day), and an adequate trial of at least 12-16 weeks is needed for sufficient effect. When the response to an SSRI is partial, a strategy of adding an antipsychotic (risperidone 0.5-2 mg, aripiprazole 5-15 mg) can be effective. However, antipsychotic monotherapy is not as effective as SSRI monotherapy in BDD, which differs from ordinary delusional disorder.

BDD delusional type — cognitive behavioral therapy: Exposure and response prevention (ERP) and cognitive restructuring are the core of evidence-based psychotherapy for BDD. An exposure hierarchy is set for mirror checking, comparison, and avoidance behaviors, and compulsive behaviors are gradually reduced. Participation in CBT may be difficult when the absence of insight at delusional level is severe, but approaching it by focusing on symptom-related distress and functional decline can raise motivation to participate.

Treatment of litigious paranoia: Antipsychotics (low-dose risperidone, olanzapine) may help reduce paranoid preoccupation, but the patient's treatment resistance is often very strong. A supportive, motivation-enhancing approach focusing on the distress and functional impairment associated with the litigation preoccupation is more effective than trying to directly stop the litigation behavior itself. Setting boundaries through family education so that the family does not take part in the litigation behavior is important. When there is dangerous behavior (threats, physical approach), linkage with judicial authorities is needed.


11. Prognosis

The prognosis of other persistent delusional disorders (F22.8) varies by subtype, and in the BDD delusional type there is a possibility of improvement with treatment, but a chronic course is common.

Prognosis of the BDD delusional type: Significant symptom improvement is reported in about 50-70% of BDD patients with SSRI treatment. The response to SSRIs in the delusional type is reported to be at a level similar to the non-delusional type, so delusionality is known not to be a predictor of SSRI treatment response. However, complete remission is uncommon, and relapse is common when treatment is stopped. Suicide risk is a particularly important prognosis-related factor, and 20-30% of BDD patients are reported to have a lifetime history of suicide attempts. Good prognostic factors include early diagnosis and treatment, SSRI response, family support, and maintained employment. Poor prognostic factors include severe delusion, suicidal ideation, preoccupation with seeking cosmetic surgery, and long diagnostic delay.

Prognosis of litigious paranoia: Generally follows a chronic course, and spontaneous remission is uncommon. Persistent impairment of occupational and social relationships is characteristic. The response to antipsychotics is often only partial relief rather than complete disappearance of the delusion. In some cases, losing a lawsuit, legal punishment, or resolution of conflict with others becomes an occasion for partial relief of symptoms.

Suicide risk management: In the BDD delusional type, suicide risk assessment and prevention are core components of treatment. Regular assessment of suicidal ideation, preparing a safety plan, and inpatient treatment when needed are recommended.


12. Prevention

Prevention of other persistent delusional disorders (F22.8), especially the BDD delusional type, centers on reducing sociocultural pressure related to appearance, early detection, and early cognitive behavioral therapy intervention for initial symptoms.

Media literacy and sociocultural interventions: Education in the ability to critically evaluate media images presenting unrealistic appearance standards (media literacy) should be provided to adolescents. There is evidence that appearance comparison on social media and excessive filter use raise the risk of BDD onset, so health education on how social media is used contributes to prevention. School-based body-image-positive education programs are reported to have a BDD prevention effect in adolescents.

Strengthening early detection: BDD screening education for dermatology, plastic surgery, dental, and orthodontic staff can reduce diagnostic delay. Using a BDD screening tool (BDDQ) before surgery or procedures and establishing a clinical pathway that makes psychiatric consultation mandatory on a positive screen are recommended. Screening that includes BDD-specific symptoms should be done in adolescent mental health programs.

Prevention of childhood trauma: Appearance-related teasing, physical abuse, and sexual abuse are risk factors for BDD onset, so early mental health intervention for children and adolescents exposed to such traumatic experiences contributes to BDD prevention. Education on preventing appearance-related bullying should be included in school violence prevention programs.


13. References

  1. Phillips KA. Body Dysmorphic Disorder: Advances in Research and Clinical Practice. Oxford University Press. 2017. ISBN: 9780190464929.

  2. Veale D, Gournay K, Dryden W, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behaviour Research and Therapy. 1996;34(9):717-729. DOI: 10.1016/0005-7967(96)00025-3. PMID: 8936752.

  3. Phillips KA, McElroy SL, Keck PE Jr, et al. Body dysmorphic disorder: 30 cases of imagined ugliness. American Journal of Psychiatry. 1993;150(2):302-308. DOI: 10.1176/ajp.150.2.302. PMID: 8422082.

  4. Gunstad J, Phillips KA. Axis I comorbidity in body dysmorphic disorder. Comprehensive Psychiatry. 2003;44(4):270-276. DOI: 10.1016/S0010-440X(03)00088-9. PMID: 12923706.

  5. Feusner JD, Yaryura-Tobias J, Saxena S. The pathophysiology of body dysmorphic disorder. Body Image. 2008;5(1):3-12. DOI: 10.1016/j.bodyim.2007.11.002. PMID: 18234571.

  6. McKay D, Gosselin JT, Gupta S. Body dysmorphic disorder. In: Handbook of Child and Adolescent Anxiety Disorders. New York: Springer; 2011:295-311.

  7. Lochner C, Stein DJ. Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders. Psychopathology. 2010;43(6):389-396. DOI: 10.1159/000321070. PMID: 20861683.

  8. Mullen PE, Lester G. Vexatious litigants and unusually persistent complainants and petitioners: from querulous paranoia to querulous behaviour. Behavioral Sciences & the Law. 2006;24(3):333-349. DOI: 10.1002/bsl.671. PMID: 16773652.

  9. Crerand CE, Franklin ME, Sarwer DB. Body dysmorphic disorder and cosmetic surgery. Plastic and Reconstructive Surgery. 2006;118(7):167e-180e. DOI: 10.1097/01.prs.0000242500.28431.24. PMID: 17149421.

  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Washington, DC: APA; 2013. (See the BDD delusional subtype classification criteria.)